INOMAX Dosing and Administration7 |
INOMAX® is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.
INOMAX Important Safety Information (ISI)
INOMAX should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood
Dosing
- Initiate at the recommended 20 ppm
- Expect significant improvement in oxygenation in most patients
- Maintain treatment until hypoxemia has resolved or for up to 14 days
- Wean cautiously and do not discontinue abruptly
The safety and effectiveness of INOMAX have been established in a patient population receiving other therapies for hypoxic respiratory failure, including vasodilators, intravenous fluids, bicarbonate therapy, and mechanical ventilation.
Please see Full Prescribing Information.
References
1. Angus DC, Clermont G, Watson RS, Linde-Zwirble WT, Clark RH, Roberts MS. Cost-effectiveness of inhaled nitric oxide in the treatment of neonatal respiratory failure in the United States. Pediatrics. 2003;112(6 Pt 1):1351-1360.